ArticleThe Journal of clinical investigation2004
A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression.
Article in The Journal of clinical investigation, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours.International journal of molecular sciences · 2017Pooled it
- Circulating thyroid stimulating hormone receptor messenger RNA and differentiated thyroid cancer: A diagnostic meta-analysis.Oncotarget · 2017Pooled it
- Portable Multispectral Optoelectronic System for Thyroid Cancer Detection.Sensors (Basel, Switzerland) · 2026Article
- Distinct ALK Expression Patterns Are Associated with Canonical and Noncanonical STRN::ALK Transcript Architectures in Oncocytic Thyroid Neoplasms.Endocrine pathology · 2026Article
- Comprehensive Proteomics and Machine Learning Analysis to Distinguish Follicular Adenoma and Follicular Thyroid Carcinoma from Indeterminate Thyroid Nodules.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Transcriptomic analysis reveals thatGenes & diseases · 2024Article
- Article
- In-silico studies to recognize repurposing therapeutics toward arginase-I inhibitors as a potential onco-immunomodulators.Frontiers in pharmacology · 2023Article
- Aberrant Expression of Thymosin Beta-4 Correlates With Advanced Disease and BRAF V600E Mutation in Thyroid Cancer.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2022Article
- Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.Journal for immunotherapy of cancer · 2022Article
- Review
- Evidence of Cooperation between Hippo Pathway andCancers · 2021Article
- Article
- Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma.Oncoimmunology · 2021Article
- A Novel Nanoproteomic Approach for the Identification of Molecular Targets Associated with Thyroid Tumors.Nanomaterials (Basel, Switzerland) · 2020Article
- Genetic differences in follicular thyroid carcinoma between Asian and Western countries: a systematic review.Gland surgery · 2020Review
- The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines.Oncoimmunology · 2020Article
- AATF and SMARCA2 are associated with thyroid volume in Hashimoto's thyroiditis patients.Scientific reports · 2020Article
- Immune Landscape of Thyroid Cancers: New Insights.Frontiers in endocrinology · 2020Review
- Myeloid Cell-Derived Arginase in Cancer Immune Response.Frontiers in immunology · 2020Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Accurate diagnosis of thyroid tumors is challenging. A particular problem is distinguishing between follicular thyroid carcinoma (FTC) and benign follicular thyroid adenoma (FTA), where histology of fine-needle aspirates is not conclusive. It is often necessary to remove healthy thyroid to rule out carcinoma. In order to find markers to improve diagnosis, we quantified gene transcript expression from FTC, FTA, and normal thyroid, revealing 73 differentially expressed transcripts (P < or = 0.0001). Using an independent set of 23 FTCs, FTAs, and matched normal thyroids, 17 genes with large expression differences were tested by real-time RT-PCR. Four genes (DDIT3, ARG2, ITM1, and C1orf24) differed between the two classes FTC and FTA, and a linear combination of expression levels distinguished FTC from FTA with an estimated predictive accuracy of 0.83. Furthermore, immunohistochemistry for DDIT3 and ARG2 showed consistent staining for carcinoma in an independent set 59 follicular tumors (estimated concordance, 0.76; 95% confidence interval, [0.59, 0.93]). A simple test based on a combination of these markers might improve preoperative diagnosis of thyroid nodules, allowing better treatment decisions and reducing long-term health costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.